An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
Conclusions:
The dose escalation of a grass pollen allergoid can be accelerated with safety and tolerability profiles comparable to the conventional dose escalation.
Source: Epidemiologic Perspectives and Innovations - Category: Epidemiology Authors: A. ChakerB. Al-KadahU. LutherU. NeumannM. Wagenmann Source Type: research
More News: Epidemiology | Immunotherapy